参考文献/References:
[1]Maurice J,Manousou P.Non-alcoholic fatty liver disease[J].Clin Med (Lond),2018,18(3):245-250.[2]王雨,林志健,边猛,等.维药菊苣提取物对高尿酸血症状态下肠道屏障的影响[J].中华中医药杂志,2018,33(5):1718-1723.[3]吴云,李春苗,刘喃喃,等.非酒精性脂肪性肝病大鼠肠粘膜紧密连接蛋白ZO-1及肌球蛋白轻链激酶的变化[J].现代生物医学进展,2017,17(30):5832-5836.[4]Monteiro AC,Parkos CA.Intracellular mediators of JAM-A-dependent epithelial barrier function[J].Ann N Y Acad Sci,2012,1257:115-124.[5]夏凡,周本杰.肠-肝轴功能紊乱在非酒精性脂肪肝病发病机制中的作用及相关治疗策略[J].世界华人消化杂志,2018,26(24):1439-1447.[6]Devlin AS,Fischbach MA.A biosynthetic pathway for aprominent class of microbiota-derived bile acids[J].Nat Chem Biol,2015,11(9):685-690.[7]Luo ZL,Cheng L,Wang T,et al.Bile acid transporters areexpressed and heterogeneously distributed in rat bileducts[J].Gut Liver,2019,13(5):569-575.[8]Zhang Y,La Certe C,Kansra S,et al.Comparative potency of obeticholic acid and natural bile acids on FXR in hepatic and intestinal in vitro cell models[J].Pharmacol Res Perspect,2017,5(6):368-378.[9]杜沅沁,徐健,黄晶晶,等.胆汁酸与糖脂代谢的关系及其在非酒精性脂肪性肝病中的发病机制及潜在价值[J].生命的化学,2022,42(10):1820-1827.[10]Min HK,Kapoor A,Fuchs M,et al.Increasedhepaticsynthesis and dysregulation of cholesterol metabolism isassociated with the severity of nonalcoholic fatty liverdisease[J].Cell Metab,2012,15(5):665-674.[11]Ferslew BC,Xie G,Johnston CK,et al.Altered bile acidmetabolome in patients with nonalcoholic steatohepatitis[J].Dig Dis Sci,2015,60(11):3318-3328.[12]施铃灵,曹亮,张振中,等.肠黏膜屏障改变对非酒精性脂肪性肝病的影响[J].胃肠病学,2019,24(2):123-126.[13]Luck H,Khan S,Kim JH,et al.Gut-associated IgA(+) immune cells regulate obesity-related insulin resistance[J].Nat Commun,2019,10(1):3650.[14]Kawai T,Akira S.The role of pattern-recognition receptorsin innate immunity:update on Toll-like receptors[J].Nat Immunol,2010,11(5):373-384.[15]Milosevic I,Vujovic A,Barac A,et al.Gut Microbiota,and Its Modulation in the Management of Liver Diseases:A Review of the Literature[J].Int J Mol Sci,2019,20(2):395.[16]Sharpton SR,Ajmera V,Loomba R.Emerging Role of the Gut Microbiome in Nonalcoholic Fatty Liver Disease: From Composition to Function[J].Clin Gastroenterol Hepatol,2019,17(2):296-306.[17]Loomba R,Seguritan V,Li W,et al.Gut Microbiome-Based Metagenomic Signature for Non-invasive Detection of Advanced Fibrosis in Human Nonalcoholic Fatty Liver Disease[J].Cell Metab,2017,25:1054-1062.[18]Tripathi A,Debelius J,Brenner DA,et al.The gut-liver axis and the intersection with the microbiome[J].Nat Rev Gastroenterol Hepatol,2018,15(7):397-411.[19]徐子媛,安凯,刘雨,等.Toll样受体在代谢相关脂肪性肝病发生发展中的作用[J].胃肠病学和肝病学杂志,2022,31(10):1086-1088.[20]Rivera CA,Adegboyega P,Van Rooijen N,et al.Toll-like receptor-4 signaling and Kupffer cells play pivotal roles in the pathogenesis of non-alcoholic steatohepatitis[J].J Hepatol,2007,47:571-579.[21]Vajro P,Paolella G,Fasano A.Microbiota andgut-liver axis:their influences on obesity and obesity-related liver disease[J].J Pediatr Gastroenterol Nutr,2013,56(5):461-468.[22]Ferolla SM,Armiliato GN,Couto CA,et al.gThe role of intestinal bacteria overgrowth in obesity-related nonalcoholic fatty liver disease[J].Nutrients,2014,6(12):5583-5599.[23]Spruss A,Kanuri G,Wagnerberger S,et al.Toll-like receptor 4 is involved in the development offructose-induced hepatic steatosis in mice[J].Hepatology,2009,50(4):1094-1104.[24]Zhu L,Baker SS,Gill C,et al.Characterizationof gut microbiomes in nonalcoholic steatohepatitis(NASH)patients:a connection between endogenousalcohol and NASH[J].Hepatology,2013,57(2):601-609.[25]张振,李政国,李倩,等.益生菌对克罗恩病患者肠道屏障功能和免疫调节的影响[J].中国微生态学杂志,2022,34(11):1314-1319.[26]李倩倩,崔伯塔,张发明.全球菌群移植现状与趋势[J].中华炎性肠病杂志,2019,3(3):208-212.[27]Zhou D,Pan Q,Shen F,et al.Total fecal microbiota transplantation alleviates high-fat diet-induced steatohepatitis in mice via beneficial regulation of gut microbiota[J].Sci Rep,2017,7(1):1529.[28]高川,姚宜山,周奎臣,等.奥贝胆酸联合白藜芦醇对小鼠非酒精性脂肪性肝病的治疗作用[J].中国药理学与毒理学杂志,2022,36(5):338-345.[29]张园园,严君君,张培,等.黄连素调节肠道菌群减轻非酒精性脂肪性肝病肝脏炎症的实验研究[J].胃肠病学,2018,23(4):209-215.[30]Peng JH,Leng J,Tian HJ,et al.Geniposide and chloro-genic acid combination ameliorates non-alcoholic steatohep-atitis involving the protection on the gut barrier function inmouse induced by high-fat diet[J].Front Pharmacol,2018,9:1399.[31]Chen M,Hou P,Zhou M,et al.Resveratrol attenuates high-fat diet-induced non-alcoholic steatohepatitis by maintaining gut barrier integrity and inhibiting gut inflammation through regulation of the endocannabinoid system[J].Clin Nutr,2020,39(4):1264-1275.
相似文献/References:
[1]龙 颖,李运泽,汤中敏,等.非酒精性脂肪性肝病与血尿酸水平测定及其临床意义[J].医学信息,2018,31(07):92.[doi:10.3969/j.issn.1006-1959.2018.07.029]
LONG Ying,LI Yun-ze,TANG Zhong-min,et al.Determination of Serum Uric Acid Level and its Clinical Significance in Non-alcoholic Fatty Liver Disease[J].Journal of Medical Information,2018,31(10):92.[doi:10.3969/j.issn.1006-1959.2018.07.029]
[2]冯贺强,张彩红.肠道菌群与非酒精性脂肪肝关系的研究进展[J].医学信息,2018,31(12):47.[doi:10.3969/j.issn.1006-1959.2018.12.015]
FENG He-qiang,ZHANG Cai-hong.Research Progress on the Relationship between Intestinal Flora and Nonalcoholic Fatty Liver[J].Journal of Medical Information,2018,31(10):47.[doi:10.3969/j.issn.1006-1959.2018.12.015]
[3]郑 颖,孙华胜,毛乾国.中医防治非酒精性脂肪性肝病研究进展[J].医学信息,2018,31(15):25.[doi:10.3969/j.issn.1006-1959.2018.15.010]
ZHENG Ying,SUN Hua-sheng,MAO Qian-guo.Progress in Prevention and Treatment of Nonalcoholic Fatty Liver Disease by TCM[J].Journal of Medical Information,2018,31(10):25.[doi:10.3969/j.issn.1006-1959.2018.15.010]
[4]李珊珊,陈少彬,龚先琼.中药单体治疗非酒精性脂肪性肝病研究进展[J].医学信息,2018,31(21):24.[doi:10.3969/j.issn.1006-1959.2018.21.008]
LI Shan-shan,CHEN Shao-bin,GONG Xian-qiong.Advances in Research of Traditional Chinese Medicine Monomer in the Treatment of
Non-alcoholic Fatty Liver Disease[J].Journal of Medical Information,2018,31(10):24.[doi:10.3969/j.issn.1006-1959.2018.21.008]
[5]黄玲玉,孙 东,蒋本君,等.天津市某区域体检人群非酒精性脂肪肝调查分析[J].医学信息,2019,32(04):99.[doi:10.3969/j.issn.1006-1959.2019.04.032]
HUANG Ling-yu,SUN Dong,JIANG Ben-jun,et al.Investigation and Analysis of Non-alcoholic Fatty Liver Disease in Medical Examination Population in
A Certain Area of Tianjin[J].Journal of Medical Information,2019,32(10):99.[doi:10.3969/j.issn.1006-1959.2019.04.032]
[6]余 辉,李 岳,郭宝娜.非酒精性脂肪性肝病的治疗研究[J].医学信息,2019,32(14):38.[doi:10.3969/j.issn.1006-1959.2019.14.014]
YU Hui,LI Yue,GUO Bao-na.Treatment of Non-alcoholic Fatty Liver Disease[J].Journal of Medical Information,2019,32(10):38.[doi:10.3969/j.issn.1006-1959.2019.14.014]
[7]王佳欣,毛乾国.慢性乙型肝炎合并非酒精性脂肪性肝病
中医辨治的研究进展[J].医学信息,2019,32(16):38.[doi:10.3969/j.issn.1006-1959.2019.16.012]
WANG Jia-xin,MAO Qian-guo.Advances in Research on TCM Syndrome Differentiation of Chronic Hepatitis B with
Nonalcoholic Fatty Liver Disease[J].Journal of Medical Information,2019,32(10):38.[doi:10.3969/j.issn.1006-1959.2019.16.012]
[8]蒋晓倩,梁惠卿,刘垚昱,等.吴耀南运用“浊毒”理论论治非酒精性脂肪性肝病验案举隅[J].医学信息,2020,33(04):158.[doi:10.3969/j.issn.1006-1959.2020.04.052]
[9]蔡秀媛,吴春城,梁惠卿,等.非酒精性脂肪性肝病中医证型与客观指标的相关性[J].医学信息,2020,33(09):21.[doi:10.3969/j.issn.1006-1959.2020.09.008]
CAI Xiu-yuan,WU Chun-cheng,LIANG Hui-qing,et al.Correlation Between TCM Syndromes of Nonalcoholic Fatty Liver Disease and Objective Indexes[J].Journal of Medical Information,2020,33(10):21.[doi:10.3969/j.issn.1006-1959.2020.09.008]
[10]徐云云,刘尚全.钠-葡萄糖协同转运蛋白2抑制剂治疗2型糖尿病合并非酒精性脂肪肝病的研究[J].医学信息,2021,34(01):33.[doi:10.3969/j.issn.1006-1959.2021.01.010]
XU Yun-yun,LIU Shang-quan.Study of Sodium-glucose Cotransporter 2 Inhibitor in the Treatment of Type 2 Diabetes with Non-alcoholic Fatty Liver Disease[J].Journal of Medical Information,2021,34(10):33.[doi:10.3969/j.issn.1006-1959.2021.01.010]